Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfacon-2 + tenofovir alafenamide
- Development stage
- Phase 3
- Lead developer
- Kawin Technology
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Combination of **peginterferon alfacon-2** (a pegylated form of recombinant interferon alpha with immunomodulatory and antiviral effects) and **tenofovir alafenamide** (a nucleotide reverse transcriptase inhibitor prodrug) used primarily for the treatment of **chronic hepatitis B (CHB)**. Peginterferon alfacon-2 stimulates the immune response against hepatitis B virus, while tenofovir alafenamide is converted in hepatocytes to the active metabolite tenofovir diphosphate, which inhibits hepatitis B virus polymerase (reverse transcriptase), terminating viral DNA synthesis. This combination aims to achieve higher functional cure rates than monotherapy, offering both direct antiviral effects and immune modulation. Studied in both adults and pediatric populations, with evidence of functional cure and safety profile documented for both groups[1][3][4].
- Other names
- pegifn-alfacon-2 + tafpegylated interferon alfa + tenofovir alafenamidepeginterferon alfa + tenofovir alafenamide
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfacon-2 + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfacon-2 + tenofovir alafenamide.